Qiagen N.v. · NYSE:QGEN

Qiagen — Investor Day (November 2016)

12 slides from Qiagen's investor day presentation, Nov 15, 2016

  1. Slide 1: Molecular Diagnostics: Addressing urgent healthcare issues with innovative solutions

    Molecular Diagnostics: Addressing urgent healthcare issues with innovative solutions Thierry Bernard Senior Vice President, Head of Molecular Diagnostics Business Area November 15, 2016 Sample to Insight 2016 Analyst & Investor Day 1

  2. Slide 2: Disclaimer

    Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended

  3. Slide 3: Sample to Insight

    *Cleveland Clinic 2017 Medical Innovations Sample to Insight 2016 Analyst & Investor Day 3

  4. Slide 4: QIAGEN is addressing urgent healthcare issues with innovative solutions

    Molecular Diagnostics Waltham, Manchester, Massachusetts England Thierry Bernard Senior Vice President, Business Area Hilden, Shenzen, Molecular Diagnostics Germany China Joined QIAGEN in 2015 2015 total sales: $637 million Germantown, Wroclaw, Molecular Diagnostics employees: ~500 Maryland Poland A

  5. Slide 5: Key trends in molecular diagnostics

    Key trends in molecular diagnostics QIAGEN implications  MDx: Fastest growth within IVD sector  Focus and differentiation to avoid price wars  Untapped potential in emerging markets  Invest in local teams and partners  Cost pressures and need for clinical value  Showing clinical benefits requi

  6. Slide 6: QIAGEN's differentiated offering addressing urgent healthcare needs

    Covering the most attractive Molecular Diagnostics segments  QIAGEN’s differentiated offering addressing urgent healthcare needs:  Immune Monitoring  Oncology  Infectious Diseases  Complete Sample to Insight solutions: Scalable workflows using different technologies Our ambition: A QIAGEN Sampl

  7. Slide 7: Strategy: Strengthen our top 3 leadership position with differentiated portfolios

    Immune Monitoring: Expand QuantiFERON benefits 2020 sales target: >$300 million from QuantiFERON-TB Oncology: Accelerate lead in Personalized Healthcare Expanding offering from PCR to NGS with GeneReader Infectious Diseases: Maximize portfolio strengths QIAsymphony as flagship automation solution De

  8. Slide 8: QuantiFERON-TB: Drive commercial success through targeted global actions

    Total Immune Monitoring: Expand QuantiFERON benefits convertible skin test market: 2020 target: >$300 million sales ~65 million  Intensify commercial activities in strategic markets tests annually  Automation upgrades to improve workflow North America  Continue menu expansion China  Market: ~15

  9. Slide 9: Providing critical diagnostic solutions across clinical disease progression

    Oncology: Accelerate lead in Personalized Healthcare Enabling insights along cancer care continuum Industry-leading pharma collaborations Cervical Lung Colon Breast Hematology NEW digene GeneReader NGS therascreen ipsogen The proven gold standard First complete Sample to No. 1 portfolio of solid tum

  10. Slide 10: Highly versatile QIAsymphony as foundation for Infectious Diseases expansion

    Infectious Diseases: Maximize portfolio strengths Broad menu Broad menu offering on one Open Continuous Random system? channel? loading? access?     -  - - 24% ~40% -  - - 76% ~60% - -   -  - - Roche: cobas 4800, BD: BD MAX, Hologic:Panther, Abbott: m2000 QIAsymphony cumulative placements F

  11. Slide 11: Active pipeline to develop new innovations enhancing our leadership positions

    Deliver innovations: Enhance our focused market leadership positions 2017 2018-2020 Menu expansion System enhancements Infectious diseases GeneReader Breast cancer NGS system enhancements GeneReader v1.1 (RUO) (Incl. open channel) Comprehensive NGS System Oncohematology Cancer Panel (RUO) and additi

  12. Slide 12: Unique portfolio of solutions from LDT to IVD tests

    Unique portfolio of solutions from LDT to IVD tests Focus on significant unmet needs with differentiation Offering complete, scalable solutions across continuum Delivering to labs a one-stop shop for molecular solutions Sample to Insight 2016 Analyst & Investor Day 12

Qiagen — Investor Day (November 2016) on 6ix